Bosset A J, Vogt P, Eeckhout E, van Melle G, Monnier P, Schaller M D, Stauffer J C, Kappenberger L, Goy J J
Division de Cardiologie, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Suisse.
Ann Cardiol Angeiol (Paris). 1997 May-Jun;46(5-6):303-10.
The objective of this study was to analyse the long-term mortality and morbidity of a group of patients undergoing thrombolysis during the acute phase of myocardial infarction and to determine the factors influencing the prognosis. One hundred and seventy five patients (149 mean and 26 women, mean age: 54 years) were included in a randomized study, comparing the efficacy of 2 thrombolytic substances administered during the acute phase of myocardial infarction. A standard questionnaire was sent to the various attending physicians to follow-up of these 175 patients.
The hospital mortality was 5% (9 patients) and 14 patients (9%) died after a mean follow-up of 4.3 +/- 2.1 years. The 5-year actuarial survival was 81%. Fourteen patients (8%) were lost to follow-up and 49 patients (32%) underwent surgical or percutaneous revascularization during follow-up. Revascularized patients had a significantly better survival than non-revascularized patients. The mean left ventricular ejection fraction of patients who died was lower (48% versus 71%) than that of survivors. Patients with an ejection fraction < 40% also had a significantly lower survival (p = 0.01). Patency of the vessel after thrombolysis was associated with a slightly better survival; this difference was not significant. The ejection fraction at 6 month was also significantly higher (60 +/- 10% versus 49 +/- 11%) for patients with a patent artery. Three risk factors for death or reinfarction were identified: age > 65 years at the time of infarction, disease in more than one coronary vessel and absence of angina pectoris before infarction. The probability of a coronary accident varied from 2 to 88% according to the number of risk factors present. At the time of follow-up, 60% of patients presented hypercholesterolaemia versus only 7% before infarction 73% of patients received anticoagulant or antiaggregant treatment and 81% of patients were asymptomatic.
The mortality and the acute and long-term morbidity of myocardial infarction remain high, as only 34% of our patients did not develop any events during follow-up, despite serious medical management and follow-up. The ejection fraction has an important prognostic value. Patient management should take the abovementioned risk factors into account.
本研究旨在分析一组在心肌梗死急性期接受溶栓治疗患者的长期死亡率和发病率,并确定影响预后的因素。175例患者(149例男性和26例女性,平均年龄:54岁)纳入一项随机研究,比较两种溶栓药物在心肌梗死急性期的疗效。向各位主治医生发送了一份标准问卷,以对这175例患者进行随访。
医院死亡率为5%(9例患者),平均随访4.3±2.1年后,有14例患者(9%)死亡。5年精算生存率为81%。14例患者(8%)失访,49例患者(32%)在随访期间接受了外科或经皮血管重建术。接受血管重建术的患者生存率明显高于未接受血管重建术的患者。死亡患者的平均左心室射血分数低于幸存者(48%对71%)。射血分数<40%的患者生存率也明显较低(p=0.01)。溶栓后血管通畅与稍好的生存率相关;这种差异不显著。血管通畅患者在6个月时的射血分数也明显更高(60±10%对49±11%)。确定了三个死亡或再梗死的危险因素:梗死时年龄>65岁、多支冠状动脉病变以及梗死前无心绞痛。根据存在的危险因素数量,冠状动脉意外的概率从2%到88%不等。在随访时,60%的患者出现高胆固醇血症,而梗死前仅为7%;73%的患者接受了抗凝或抗血小板治疗,81%的患者无症状。
心肌梗死的死亡率以及急性和长期发病率仍然很高,尽管进行了认真的医疗管理和随访,但我们的患者中只有34%在随访期间未发生任何事件。射血分数具有重要的预后价值。患者管理应考虑上述危险因素。